[Ip-health] Open Letter with signatures on WHA transparency resolution

James Love james.love at keionline.org
Fri May 10 06:24:19 PDT 2019

This is the text of the open letter on the WHA transparency resolution,
with the signatures from 73 groups and 45 individuals.



May 9, 2019

Civil Society Open Letter to World Health Assembly Delegates

We are appalled at the proposals by several countries at the May 7, 2019
informal on the World Health Assembly (WHA) transparency resolution. In the
April 29, 2019 version, the resolution was focused on transparency, and
provided concrete measures to achieve the most useful and practical

The 61 brackets to the text, plus other proposed changes, would make this
resolution confusing, weak and practically useless in many areas.

It seems clear that several countries, including in particular, Germany,
Sweden, Denmark, the UK and Australia want to derail the transparency
initiative, and that Austria and the United States want to weaken key parts.

We urge other WHA Member States to participate in the May 10, 2019
informal, and to stand up for a resolution that will be effective in
empowering governments and the public to have greater transparency and more
equal access to information, in order to have greater power in dealing with
the crisis in the pricing of medical technologies.

Organizations (in alphabetical order)

1. Acceso Justo al Medicamento (AAJM), (Spain)
2. Acción Internacional para la Salud - Perú
3. Action against AIDS Germany
4. AIDES (France)
5. AIDS Access Foundation (Thailand)
6. AIDS Healthcare Foundation (AHF)
7. Alianza LAC - Global
8. All India Drug Action Network
9. American Medical Student Association (AMSA)
10. ARAS - The Romanian Association Against AIDS
11. Ärzte der Welt e.V./ Médecins du Monde Germany
12. Associação Brasileira Interdisciplinar de AIDS (ABIA) (Brazil)
13. Brot für die Welt, Bread for the World (Germany)
14. BUKO Pharma-Kampagne (Germany)
15. Canadian HIV/AIDS Legal Network
16. Cancer Alliance, South Africa
17. Cáritas Latinoamérica y el Caribe
18. Centre for Health Science and Law (CHSL)
19. Citizens' Health Initiative (Malaysia)
20. Colombian Council of Bishops
21. Committee of Oversight and Cooperation in Health (Colombia)
22. Consumers Association of Penang (CAP) (Malaysia)
23. Corporación Innovarte (Chile)
24. Doctors for America
25. EKPIZO (Consumer Association the Quality of Life) (Greece)
26. Empower India
27. End AIDS Now
28. Essential Inventions
29. European Alliance for Responsible R&D and Affordable Medicines
30. European Public Health Alliance (EPHA)
31. Fundación IFARMA (Colombia)
32. GAT- Grupo de Ativistas em Tratamentos (Portugal)
33. Global Health Advocates
34. Global Justice Now (UK)
35. Health Action International (HAI)
36. Health Action International Asia-Pacific (HAIAP)
37. Health and Trade Network (HaT)
38. Health Global Action Project (Health GAP)
39. Health Innovation in Practice (HIP)
40. Heart to Heart Foundation, Thailand
41. Institute for Agriculture and Trade Policy.
42. Interfaith Center on Corporate Responsibility (ICCR)
43. Just Treatment (UK)
44. KEI Europe (Switzerland)
45. Knowledge Ecology International (KEI)
46. Korean Pharmacists for Democratic Society (KPDS)
47. LWC Health
48. Médecins Sans Frontières (MSF) Access Campaign
49. MEZIS (Germany)
50. Misión Salud (Colombia)
51. ONG Políticas Farmacéuticas (Chile)
52. People’s Health Institute (PHI) (South Korea)
53. People’s Health Movement (PHM)
54. Positive Malaysian Treatment Access & Advocacy Group (MTAAG+)
55. Prescrire (France)
56. Public Eye (Switzerland)
57. Salud por Derecho (Spain)
58. Salud y Farmacos (USA)
59. Section 27 (South Africa)
60. Stichting Farma ter Verantwoording (Pharmaceutical Accountability
Foundation) (The Netherlands)
62. T1International
63. The Thai Network of People Living with HIV/AIDS (Thailand)
64. Third World Network (TWN)
65. Treatment Action Campaign (TAC) (South Africa)
66. Treatment Action Group (TAG)
67. Union for Affordable Cancer Treatment (UACT)
68. Universidades Aliadas por Medicamentos Essenciais (UAEM Brasil)
69. Universities Allied for Essential Medicines (UAEM)
70. Wemos (The Netherlands)
71. Yale Global Health Justice Partnership
72. Yolse (Switzerland)
73. Young Professionals Chronic Disease Network (YP-CDN)

Individuals (in alphabetical order)

1. Aidan Hollis. Professor of Economics, University of Calgary.
2. Amy Kapczynski, Professor of Law, Yale Law School.
3. Anthony Robbins, MD, MPA, Professor, Tufts University, School of
Medicine, Boston, MA, USA, Co-Editor, Journal of Public Health Policy.
4. Benjamin Mason Meier, JD, LLM, PhD, Associate Professor of Global Health
Policy, Zachary Taylor Smith Distinguished Professor of Public Policy,
Department of Public Policy, University of North Carolina at Chapel Hill.
5. Beverley F Snell, Medal of the Order of Australia (OAM), Coordinator -
Health Action International Asia Pacific.
6. Brian Citro. Assistant Clinical Professor of Law, Northwestern Pritzker
School of Law.
7. Brook K. Baker, Professor at Law, Northeastern University School of Law
8. Dinesh Abrol, National Working Group on Patent Laws, India.
9. Dr. Ellen ‘t Hoen, Medicines Law & Policy.
10. Dr. Jennifer Sellin, Assistant Professor of International & European
Law, Maastricht Centre for Human Rights, Maastricht University, and
Visiting Professor Dalla Lana School of Public Health, University of
11. Dr. Katrina Perehudoff, post doctoral researcher, University of Toronto
& Ghent University.
12. Dr. Krisantha Weerasuriya, Independent Consultant, WHO Retiree and
Former Secretary of the Expert Committee on Selection and Use of Essential
13. Dr. Mogha Kamal-Yanni, Public health and access to medicines
consultant, United Kingdom.
14. Dr. Rafael J. Pérez Miranda, Universidad Autónoma Metropolitana -
15. Fifa Rahman, Board Member Unitaid NGO Delegation and PhD Candidate
(International Trade and Intellectual Property), University of Leeds.
16. Gilberto de Lima Lopes Junior, MD, MBA, FAMS. Associate Professor of
Clinical Medicine, Medical Director for International Programs, Associate
Director for Global Oncology, Co-Leader, Lung Cancer Site Disease Group,
Sylvester Comprehensive Cancer Center at the University of Miami and the
Miller School of Medicine.
17. Graham Dutfield, Professor of International Governance, School of Law,
University of Leeds.
18. Gregg Gonsalves, Assistant Professor, Epidemiology of Microbial
Diseases, Yale School of Public Health.
19. Joel Lexchin, MD. Member Emeriti-School of Health Policy & Management,
Faculty of Health, York University.
20. John Wilbanks, Open Source advocate - United States of America.
21. Jordan Jarvis. London School of Hygiene & Tropical Medicine.
22. Lawrence Gostin, University Professor, Georgetown University,
Washington, DC
23. Marcus Low, Spotlight, South Africa.
24. Margo A. Bagley, Asa Griggs Candler Professor of Law, Emory University
School of Law, Faculty Fellow, Emory Global Health Initiative, Senior
Fellow, Centre for International Governance Innovation (CIGI),
Collaborator, Harvard University Global Access in Action (GAiA) Program.
25. Marie-Paule Kieny, PhD. Director of Research, Institut national de la
santé et de la recherche médicale (INSERM), Chair, Drugs for Neglected
Diseases Initiative Board of Directors.
26. Melissa Barber. PhD student, Harvard University.
27. Meri Koivusalo, Prof Global Health and Development, Tampere University,
28. Michael H. Davis, Professor, Cleveland-Marshall College of Law.
29. Mohan Rao, Former professor, Centre of Social Medicine and Community
Health, JNU, New Delhi, India.
30. Ophira Ginsburg, MD. Associate Professor, Department of Population
Health, Associate Professor, Department of Medicine, Director Perlmutter
Cancer Center High-Risk Cancer Genetics Program, New York University.
31. Oscar Lizarazo, Associate Professor, Universidad Nacional Colombia.
32. Peter S. Arno, PhD, Senior Fellow and Director, Health Policy Research,
Political Economy Research Institute, University of Massachusetts-Amherst,
Amherst, MA.
33. Phyllis Freeman, JD, Professor Emerita, University of Massachusetts,
Boston, MA, USA, Co-Editor, Journal of Public Health Policy.
34. Prof. Dr. H.D. Banta, former director of the Health Program US
Congressional Office of Technology Assessment and former Deputy Director of
the Pan American Health Organization.
35. Prof Dr Hans V Hogerzeil, MD, PhD, FRCP, Co-Chair, Lancet Commission on
Essential Medicines Policies, Formerly: Director for Essential Medicines
and Pharmaceutical Policies, WHO, Geneva.
36. Radha Holla Bhar (India).
37. Reshma Ramachandran, MD, Family Medicine Physician
38. Rohit Malpani, Alternate Board Member, Unitaid NGO Delegation.
39. Salomé Meyer, Cancer Alliance (South Africa).
40. Shirin Syed, IP Researcher, North Maharashtra University (NMU),
41. Sol Terlizzi, Academic Coordinator, Master in Intellectual Property,
FLACSO Argentina.
42. Suerie Moon, MPA, PhD. Director of Research at the Global Health
Centre, Graduate Institute of International and Development Studies, Geneva
and Adjunct Lecturer on Global Health at the Harvard T.H. Chan School of
Public Health.
43. Thomas Schwarz, Executive Secretary, Medicus Mundi International.
44. Uma Suthersanen, Advocate and Solicitor to the Supreme Court of
Singapore and Professor of International Intellectual Property Law, Queen
Mary, University of London.
45. Wilbert Bannenberg, Public Health Consultant, The Netherlands.

More information about the Ip-health mailing list